Two applications for the renewal of the approval of the active substance quinmerac were initially submitted on 23 and 25 April 2018 in accordance with Implementing Regulation (EU) No 844/2012 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 7 May 2018 that it had assessed the admissibility of the applications pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular their completeness and timeliness, and concluded that they were admissible. On 27 March 2021, Implementing Regulation (EU) 2020/1740 became applicable to quinmerac. A new application for its renewal of the approval was submitted in accordance with that Regulation on 27 July 2021 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 5 October 2023 that it had assessed the admissibility pursuant to Article 8 of that Regulation, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority, which conducted a public consultation on it between 19 February and 19 April 2024, pursuant to Article 10 of Implementing Regulation (EU) 2020/1740. The rapporteur Member State has not finalised the risk assessments pursuant to Article 11 of Implementing Regulation (EU) 2020/1740 and estimates that it will be able to submit the draft renewal assessment report to the Commission and the Authority in December 2026. As additional time is necessary to complete the remaining steps in the renewal procedure, the duration of the extension of the approval period should be set at 29 months, until 31 May 2029.
Recital 45, Regulation (EU) 2026/2348
In force
- celex=32012R0844